A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910